Consolidated revenue from operations stood at Rs 1,457.10 crore
Alembic Pharmaceuticals reported a 35.36 per cent rise in consolidated net profit to Rs 333.37 crore for the quarter ended September, mainly on account of robust sales.
The company had posted a net profit of Rs 246.27 crore for the corresponding period of the previous fiscal, Alembic Pharma said in a filing to BSE.
Consolidated revenue from operations stood at Rs 1,457.10 crore for the quarter under consideration. It was Rs 1,240.87 crore for the same period a year ago, it added.
“It was a strong quarter for the company led by growth in the domestic business. The International as well as API Business also continued to perform well,” Alembic Pharmaceuticals MD Pranav Amin said.
In another development, the company said its joint venture firm Aleor Dermaceuticals has received final approval from the US health regulator for anti-fungal Tavaborole Topical Solution.
Tavaborole Topical solution is an antifungal indicated for the treatment of onychomycosis of the toenails.
Aleor Dermaceuticals has received final approval from the US Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Tavaborole Topical Solution, 5 per cent, Alembic Pharmaceuticals said in a BSE filing.